No Data
Qyuns Therapeutics Shrinks Loss in H1
Quantum Hi-Tech Biological Co., Ltd. (B) released its mid-year results, achieving a revenue of 44.919 million yuan and a gross profit of 37.756 million yuan.
Quanxin Biology-B (02509) announced its unaudited interim results for the six months ended June 30, 2024, with revenue of RMB 44.919 million, and no revenue in the same period last year; gross profit of RMB 37.756 million; R&D expenses of RMB 0.145 billion. The announcement stated that the revenue comes from authorization fees and R&D service fees for QX008N and QX004N authorized transactions, reflecting the Group's strong research and development capabilities.
Express News | Qyuns Therapeutics - Appointment of Qiu Jiwan, Wu Yiliang, Lin Weidong as Executive Directors of Second Session of Board
China Create Bio-B (02509) released its interim results, achieving revenue of 44.919 million yuan.
Quanxin Biopharmaceutical-B (02509) released the unaudited interim results for the six months ending June 30, 2024,...
Qunxing Biologics-B (02509.HK) announced its interim performance. It continues to optimize the CMC quality management system and improve production efficiency, seeking opportunities for overseas expansion.
On August 15th, Grontmij released an announcement. For a six-month period ending on June 30, 2024, the group's revenue was 449.2 million yuan, which was generated from royalty income and research and development service fees from QX008N and QX004N authorized transactions, reflecting the group's strong research and development capabilities. As of July 31, 2024, the company holds 43 patents in China, including 34 invention patents and 9 utility model patents, and 9 patents overseas. As of the same date, the company also has 46 patent applications in China and overseas awaiting approval.
Express News | Qyuns Therapeutics - Hy Rev RMB44.9 Mln
No Data
